Elanco Animal Health (NYSE:ELAN – Get Free Report) had its price target hoisted by investment analysts at Barclays from $30.00 to $32.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 19.27% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, November 9th. UBS Group increased their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their target price for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, The Goldman Sachs Group started coverage on Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and an average target price of $30.36.
Read Our Latest Report on Elanco Animal Health
Elanco Animal Health Trading Up 0.5%
Shares of Elanco Animal Health stock traded up $0.13 on Thursday, hitting $26.83. The stock had a trading volume of 538,120 shares, compared to its average volume of 5,579,363. The company has a quick ratio of 1.07, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. Elanco Animal Health has a one year low of $19.40 and a one year high of $27.98. The stock’s 50-day simple moving average is $23.52 and its two-hundred day simple moving average is $23.91. The stock has a market cap of $13.41 billion, a price-to-earnings ratio of -89.74, a PEG ratio of 2.19 and a beta of 1.73.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, sell-side analysts predict that Elanco Animal Health will post 1.18 EPS for the current year.
Insiders Place Their Bets
In related news, insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the sale, the insider owned 138,911 shares in the company, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ELAN. Sapient Capital LLC increased its holdings in Elanco Animal Health by 0.3% in the 2nd quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after buying an additional 420 shares in the last quarter. Ritholtz Wealth Management lifted its stake in Elanco Animal Health by 5.0% during the 3rd quarter. Ritholtz Wealth Management now owns 9,335 shares of the company’s stock valued at $209,000 after acquiring an additional 446 shares during the period. Covestor Ltd lifted its stake in Elanco Animal Health by 48.2% during the 3rd quarter. Covestor Ltd now owns 1,383 shares of the company’s stock valued at $31,000 after acquiring an additional 450 shares during the period. Farther Finance Advisors LLC lifted its stake in Elanco Animal Health by 12.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock valued at $94,000 after acquiring an additional 464 shares during the period. Finally, North Dakota State Investment Board boosted its holdings in shares of Elanco Animal Health by 3.4% during the 3rd quarter. North Dakota State Investment Board now owns 15,132 shares of the company’s stock valued at $339,000 after acquiring an additional 496 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.
About Elanco Animal Health
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Recommended Stories
- Five stocks we like better than Elanco Animal Health
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
